Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan ; volume:12 ; number:4 ; day:12 ; month:5 ; year:2023 ; pages:2005-2021 ; date:8.2023
Ophthalmology and therapy ; 12, Heft 4 (12.5.2023), 2005-2021, 8.2023
- Urheber
-
Yanagi, Yasuo
Takahashi, Kanji
Iida, Tomohiro
Gomi, Fumi
Morii, Junko
Kunikane, Eriko
Sakamoto, Taiji
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40123-023-00715-y
- URN
-
urn:nbn:de:101:1-2023110309263228643968
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yanagi, Yasuo
- Takahashi, Kanji
- Iida, Tomohiro
- Gomi, Fumi
- Morii, Junko
- Kunikane, Eriko
- Sakamoto, Taiji
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study
Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Prognostic factors for long term visual acuity outcome after Ranibizumab Therapy in patients with neovascular age-related macular degeneration
Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study
Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Prognostic factors for long term visual acuity outcome after Ranibizumab Therapy in patients with neovascular age-related macular degeneration
Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study
Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Prognostic factors for long term visual acuity outcome after Ranibizumab Therapy in patients with neovascular age-related macular degeneration